Sun Pharma: Strong Q1 show, settlement of antitrust case pleases investors

Lack of pricing pressure, especially in the US, and debt reduction are other positives

A strong Q1, 2021-22 (Apr-Jun 2021) performance saw the share price of Sun Pharma jump by 10 per cent in a single session. The pharma major had terrific year-on-year (YoY) results, boosted by the low base of Q1, 2020-21. But it also had a pretty good quarter-on-quarter (QoQ) performance versus Jan-Mar 2021 (Q4, 2020-21).

The consolidated results saw operational revenues climbing to Rs 9,719 crore versus Rs 7,585 crore YoY and versus Rs 8,522 crore QoQ. Sales grew by double-digits YoY in all of its major markets. The PAT (ignoring associates and joint ventures) was registered at Rs 1,404 crore